Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Loos

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studiesH Gelderblom, W J Loos, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumoursO Soepenberg, A Sparreboom, M J A de Jonge, et al.
Anti-Cancer Drugs|June 23, 1999
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancerL van Zuylen, J H Schellens, S H Goey, et al.
British Journal of Cancer|November 17, 2001
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancerH Gelderblom, A Sparreboom, M J de Jonge, et al.
Anti-Cancer Drugs|April 9, 1999
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatinR H Mathijssen, R J van Alphen, M J de Jonge, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytesJ Ma, J Verweij, A S Planting, et al.
British Journal of Pharmacology|January 14, 2010
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)H Burger, A Zoumaro-Djayoon, A W M Boersma, et al.
The Journal of Organic Chemistry|December 26, 2001
Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug releaseF M de Groot, W J Loos, R Koekkoek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Irinotecan (CPT-11) metabolism and disposition in cancer patientsA Sparreboom, M J de Jonge, P de Bruijn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 1998
Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor ELA I de Vos, K Nooter, J Verweij, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studiesH Gelderblom, W J Loos, J Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumoursO Soepenberg, A Sparreboom, M J A de Jonge, et al.
Anti-Cancer Drugs|June 23, 1999
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancerL van Zuylen, J H Schellens, S H Goey, et al.
British Journal of Cancer|November 17, 2001
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancerH Gelderblom, A Sparreboom, M J de Jonge, et al.
Anti-Cancer Drugs|April 9, 1999
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatinR H Mathijssen, R J van Alphen, M J de Jonge, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytesJ Ma, J Verweij, A S Planting, et al.
British Journal of Pharmacology|January 14, 2010
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)H Burger, A Zoumaro-Djayoon, A W M Boersma, et al.
The Journal of Organic Chemistry|December 26, 2001
Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug releaseF M de Groot, W J Loos, R Koekkoek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Irinotecan (CPT-11) metabolism and disposition in cancer patientsA Sparreboom, M J de Jonge, P de Bruijn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 1998
Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor ELA I de Vos, K Nooter, J Verweij, et al.
Pageof 7